Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M, Schouten RD, De Gooijer CJ, Baas P. Muller M, et al. Among authors: de gooijer cj. Expert Rev Anticancer Ther. 2017 May;17(5):399-409. doi: 10.1080/14737140.2017.1311791. Epub 2017 Apr 3. Expert Rev Anticancer Ther. 2017. PMID: 28338376 Review.
Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Schouten RD, Muller M, de Gooijer CJ, Baas P, van den Heuvel M. Schouten RD, et al. Among authors: de gooijer cj. Lung Cancer. 2018 Dec;126:210-216. doi: 10.1016/j.lungcan.2017.11.012. Epub 2017 Nov 17. Lung Cancer. 2018. PMID: 29179916 No abstract available.
Tumour Treating Fields for mesothelioma.
de Gooijer CJ, Burgers JA. de Gooijer CJ, et al. Lancet Oncol. 2020 Jan;21(1):e9. doi: 10.1016/S1470-2045(19)30828-9. Lancet Oncol. 2020. PMID: 31908313 No abstract available.
Immunotherapy in Malignant Pleural Mesothelioma.
de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. de Gooijer CJ, et al. Front Oncol. 2020 Feb 21;10:187. doi: 10.3389/fonc.2020.00187. eCollection 2020. Front Oncol. 2020. PMID: 32154179 Free PMC article. Review.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA; NVALT19 study group. de Gooijer CJ, et al. Lancet Respir Med. 2021 Jun;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515500 Clinical Trial.
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, Aerts JG. Dammeijer F, et al. Among authors: de gooijer cj. EBioMedicine. 2021 Feb;64:103160. doi: 10.1016/j.ebiom.2020.103160. Epub 2021 Jan 27. EBioMedicine. 2021. PMID: 33516644 Free PMC article.
19 results